CClinicalTrials.gg
CompletedNCT01016652Updated Jun 19, 2018Results posted

Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients

An interventional study of etafilcon A multifocal contact lens and etafilcon A Contact Lens in Presbyopia, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 8 sites in United States. Open to participants aged 35 Years to 47 Years. Per ClinicalTrials.gov, last updated 2018-06-19.

Sponsored by Johnson & Johnson Vision Care, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
35 Years to 47 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of a multi-focal contact lens on symptomatic patients.

02

Conditions studied

  • Presbyopia

Browse trials for

03

In context

Presbyopia

324 studies on the registry are indexed under Presbyopia; 33 are open to participants now.

This study's enrollment of 49 is below the median of 61 across 265 interventional studies indexed under Presbyopia.

Browse Presbyopia studies →

Lead sponsor

Johnson & Johnson Vision Care, Inc. is the lead sponsor of 220 studies on the registry; 2 are open to participants now.

Of its 110 completed or terminated interventional studies of FDA-regulated products, 101 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 47 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • To have signed an informed consent form (documented by the investigator in the Case Report Form [CRF]).
  • Be existing daily wear spherical single-vision soft CL wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed).
  • Between 35 and 47 years of age (inclusive).
  • Have a CL spherical distance requirement between -1.00D and -6.00D (-6.50D refractive) in both eyes.
  • Refractive astigmatism of 0.75D or less in both eyes.
  • Visual symptoms associated with near vision
  • Be correctable to a visual acuity of 6/9 (20/30) or better in each eye.
  • Have normal eyes with no evidence of abnormality or disease. For the purpose of this study a normal eye is defined as one having:

    1. No amblyopia.
    2. No evidence of lid abnormality or infection.
    3. No conjunctival abnormality or infection.
    4. No clinically significant slit lamp findings (i.e. stromal haze, staining, scarring, Vascularization, infiltrates or abnormal opacities).
    5. No other active ocular disease.

Exclusion criteria

Exclusion Criteria:

  • Monovision user or multifocal CL wearer.
  • Regular user of reading spectacles (i.e. daily usage).
  • Requires concurrent ocular medication.
  • Clinically significant (Grade 3 or 4) corneal stromal haze, corneal Vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate CL wear.
  • Corneal staining Grade 3 in more than two regions.
  • Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrollment for this study.
  • Pre-existing ocular irritation that would preclude CL fitting.
  • Keratoconus or other corneal irregularity.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Other
    etafilcon A multifocal / etafilcon A sphere

    period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.

    Device: etafilcon A multifocal contact lens · Device: etafilcon A Contact Lens

  • Other
    etafilcon A sphere / etafilcon A multifocal

    period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.

    Device: etafilcon A multifocal contact lens · Device: etafilcon A Contact Lens

Interventions

  • Deviceetafilcon A multifocal contact lens

    low-add multifocal contact lens

  • Deviceetafilcon A Contact Lens

    standard sphere contact lens

06

What researchers measure

Primary outcomes

  1. Subject Reported Overall Vision Quality Using (CLUE)TM Questionnaire

    The Contact Lens User Experience (CLUE) Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response, with scores ranging from 0-120.

    Time frame: week 4

  2. Monocular Amplitude of Accommodation

    The amplitude of accommodation is a measure of the eyes ability to accommodate or focus on near objects. The method used was the push-up/push-down method performed monocularly. One eye was occluded and using the smallest print the subject was able to read, the reading chart was slowly moved towards the subject. The subject was asked them to indicate when the print first becomes blurred. The distance was noted and the amplitude of accommodation was calculated.

    Time frame: week 4

Secondary outcomes

  1. Proportion of Subjects With Near Vision Symptoms as Assessed by the NVQ

    Proportion of subjects reporting frequent/constant near vision problem per the Near Vision Questionnaire (NVQ). The NVQ was used to assess subjects' near vision problems. Subjects graded each question using a 5-level Likert-type scale (5-levels: never, infrequent, sometimes, frequently, constantly).

    Time frame: week 4

  2. Subject Reported Lens Comfort Using CLUE Questionnaire

    Subject reported lens comfort was assessed using the CLUE Questionnaire. CLUE is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. Scores range from 0 -120.

    Time frame: week 4

  3. Comfortable Wearing Time

    Comfortable wearing time was measured using self-reported subject awareness of irritation at a given time of day, rounded to the nearest half-hour. Could be described as aware of issue or completely comfortable.

    Time frame: week 4

  4. Proportion of Subjects Benefiting From the Binocular +/-1.00D Accommodative Flipper

    Utility of the use of the Binocular +/-1.00D accommodative flipper as a screening tool for those emerging presbyopia subjects

    Time frame: Baseline

07

Results

Posted Jan 23, 2014

Participant flow

This was a four week, 49 subject, doubly-masked, daily wear, two-part crossover study. Recruited patients were emerging presbyopic (35-47 years) and soft CL wearing who were experiencing any near vision symptoms.

Period 1
Participant flow — Period 1
MilestoneEtafilcon A Multifocal/ Etafilcon A SphereEtafilcon A Sphere/ Etafilcon A Multifocal
Started2524
Completed2524
Not completed00
Period 2
Participant flow — Period 2
MilestoneEtafilcon A Multifocal/ Etafilcon A SphereEtafilcon A Sphere/ Etafilcon A Multifocal
Started2524
Completed2524
Not completed00

Outcome measures

PrimarySubject Reported Overall Vision Quality Using (CLUE)TM Questionnaire

The Contact Lens User Experience (CLUE) Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response, with scores ranging from 0-120.

Time frame:
week 4
Reported as:
Median · units on a scale
Subject Reported Overall Vision Quality Using (CLUE)TM Questionnaire
units on a scaleEtafilcon A MultifocalEtafilcon A Sphere
Subject Reported Overall Vision Quality Using (CLUE)TM Questionnaire41.0 (30.0 to 51.0)39.0 (28.0 to 50.0)
Statistical analysis
  • Etafilcon A Multifocal vs Etafilcon A Sphere · Mixed Models Analysis · Mean difference (final values): -4.14 · 95% CI -9.86 to 1.59
PrimaryMonocular Amplitude of Accommodation

The amplitude of accommodation is a measure of the eyes ability to accommodate or focus on near objects. The method used was the push-up/push-down method performed monocularly. One eye was occluded and using the smallest print the subject was able to read, the reading chart was slowly moved towards the subject. The subject was asked them to indicate when the print first becomes blurred. The distance was noted and the amplitude of accommodation was calculated.

Time frame:
week 4
Reported as:
Median · diopters
Monocular Amplitude of Accommodation
dioptersEtafilcon A MultifocalEtafilcon A Sphere
Monocular Amplitude of Accommodation0.00 (-0.075 to 0.025)0.00 (-0.075 to 0.01)
Statistical analysis
  • Etafilcon A Multifocal vs Etafilcon A Sphere · Mixed Models Analysis · Mean difference (net): 0.01 · 95% CI -0.09 to 0.10
SecondaryProportion of Subjects With Near Vision Symptoms as Assessed by the NVQ

Proportion of subjects reporting frequent/constant near vision problem per the Near Vision Questionnaire (NVQ). The NVQ was used to assess subjects' near vision problems. Subjects graded each question using a 5-level Likert-type scale (5-levels: never, infrequent, sometimes, frequently, constantly).

Time frame:
week 4
Reported as:
Number · percentage of participants
Proportion of Subjects With Near Vision Symptoms as Assessed by the NVQ
percentage of participantsEtafilcon A MultifocalEtafilcon A Sphere
Proportion of Subjects With Near Vision Symptoms as Assessed by the NVQ5343
SecondarySubject Reported Lens Comfort Using CLUE Questionnaire

Subject reported lens comfort was assessed using the CLUE Questionnaire. CLUE is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. Scores range from 0 -120.

Time frame:
week 4
Reported as:
Median · units on a scale
Subject Reported Lens Comfort Using CLUE Questionnaire
units on a scaleEtafilcon A MultifocalEtafilcon A Sphere
Subject Reported Lens Comfort Using CLUE Questionnaire59.0 (38.0 to 75.0)59.0 (50.0 to 77.0)
SecondaryComfortable Wearing Time

Comfortable wearing time was measured using self-reported subject awareness of irritation at a given time of day, rounded to the nearest half-hour. Could be described as aware of issue or completely comfortable.

Time frame:
week 4
Reported as:
Median · hours
Comfortable Wearing Time
hoursEtafilcon A MultifocalEtafilcon A Sphere
Comfortable Wearing Time14 (11 to 15)14 (12 to 14.5)
SecondaryProportion of Subjects Benefiting From the Binocular +/-1.00D Accommodative Flipper

Utility of the use of the Binocular +/-1.00D accommodative flipper as a screening tool for those emerging presbyopia subjects

Time frame:
Baseline
Reported as:
Number · percentage of participants
Proportion of Subjects Benefiting From the Binocular +/-1.00D Accommodative Flipper
percentage of participantsEtafilcon A MultifocalEtafilcon A Sphere
Proportion of Subjects Benefiting From the Binocular +/-1.00D Accommodative Flipper5258

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etafilcon A Multifocal—0/49 (0%)0/49 (0%)
Etafilcon A Sphere—0/49 (0%)0/49 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Etafilcon A Multifocal/ Etafilcon A SphereEtafilcon A Sphere\ Etafilcon A MultifocalTotal
<=18 years000
Between 18 and 65 years252449
>=65 years000
Age, Continuous
Age, Continuous(years)Etafilcon A Multifocal/ Etafilcon A SphereEtafilcon A Sphere\ Etafilcon A MultifocalTotal
Mean42.3 ± 3.442.3 ± 3.442.3 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)Etafilcon A Multifocal/ Etafilcon A SphereEtafilcon A Sphere\ Etafilcon A MultifocalTotal
Female181836
Male7613
08

Study locations

8 sites
  • North Little Rock, Arkansas, United States
  • Blue Springs, Missouri, United States
  • Lake Ozark, Missouri, United States
  • Warren, Ohio, United States
  • Kittanning, Pennsylvania, United States
  • Warwick, Rhode Island, United States
  • Chamberlain, South Dakota, United States
  • Burlington, Vermont, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01016652
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Collaborators
Visioncare Research Ltd.
Responsible party
Sponsor
First posted
Nov 19, 2009
Start date
Oct 1, 2009
Primary completion
Dec 1, 2009
Completion
Dec 1, 2009
Results posted
Jan 23, 2014
Last update
Jun 19, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion